Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Visual outcomes in relation to time to treatment in neovascular age-related macular degeneration

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Long-term visual outcome in a Danish population of patients with idiopathic intracranial hypertension

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Bilateral diffuse uveal melanocytic proliferation: Case report and literature review

    Research output: Contribution to journalReviewResearchpeer-review

  3. Intraocular surgery - assessment and transfer of skills using a virtual-reality simulator

    Research output: Contribution to journalReviewResearchpeer-review

  1. The Natural History of Inherited Retinal Dystrophy due to Biallelic Mutations in the RPE65 Gene

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Diabetic Macular Edema Treated with Anti–Vascular Endothelial Growth Factor: Considerations Related to Nonimprovers

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Incidence of diabetic eye disease among migrants: a cohort study of 100,000 adults with diabetes in Denmark

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Cardiolipin Synthesis in Brown and Beige Fat Mitochondria Is Essential for Systemic Energy Homeostasis

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

PURPOSE: To study the relation between the interval from diagnosis to initiation of intravitreal injection therapy and visual outcome in neovascular age-related macular degeneration (nAMD) and to report changes over time in fellow-eye status.

METHODS: Retrospective chart review. The study included 1185 eyes in 1099 patients who began vascular endothelial growth factor inhibitor treatment for nAMD during four separate periods in 2007, 2009, 2011 and 2012 using a fixed loading-dose regimen of three ranibizumab injections.

RESULTS: Mean best-corrected visual acuity (BCVA) at presentation remained within the range 0.23-0.24 Snellen and the median patient age within 79-80 years, whereas BCVA at first visit after the third injection increased from 0.24 to 0.31 (p < 0.0001) in concert with a shift in preferred practice from separate-day injection to same-day injection. This led to a reduction in the median time to treatment from 16 days to 1 day. The proportion of patients with fellow-eye BCVA 0.05 or worse at presentation with newly diagnosed wet AMD in the incident eye decreased from 38% to 22% (p < 0.0018). The proportion of bilaterally treated patients increased during the study period.

CONCLUSION: In this study, 2-week-earlier injection was associated with the equivalent of a 5-Early Treatment Diabetic Retinopathy Study letter-gain in mean visual acuity at 3 months after presentation. The difference is larger than expected from the 2-week-longer duration of disease at the study end-point. The study supports that early diagnosis and treatment of nAMD is of value for functional outcomes.

Original languageEnglish
JournalActa Ophthalmologica
Volume93
Issue number7
Pages (from-to)616-20
Number of pages5
ISSN1755-375X
DOIs
StatePublished - Nov 2015

ID: 45977540